Product category:
Evaporation equipment
News Release from: Genevac
Edited by the Laboratorytalk Editorial
Team on 11 April 2007
Genevac acquired by Riverlake Partners
Riverlake Partners, a Portland USA-based private equity firm, announced the acquisition of Genevac from Thermo Fisher Scientific
Genevac is a leading global manufacturer of high performance solvent evaporation systems for drug discovery, molecular biology and life science research markets Neither the structure terms nor the value of the transaction were disclosed
This article was originally published on Laboratorytalk on 21 Jul 2008 at 8.00am (UK)
Related stories
Large freeze dryer accelerates pilot scale work
Genevac has announced the introduction of the VirTis VirTual large capacity pilot scale freeze-dryer designed for fast drying and high condenser loading applications
Sample preparation method helps curb sports doping
A new customer application report available from Genevac discusses an improved method for the preparation of samples for the mass spectroscopic detection of synthetic insulin in blood serum
MVC Capital participated in the financing, in conjunction with Riverlake.
Riverlake will merge Genevac into its platform investment, SP Industries (SP) to create a dynamic global equipment company.
Other SP brands include HotPack, Virtis and FTS, which was acquired in October 2006.
Further reading
Freeze dryers for pilot scale or research
Genevac has announced the introduction of the VirTis Genesis freeze drying system offering unmatched versatility for pilot, research or small scale applications
Concentrate samples without losing volatiles
Genevac has developed in conjunction with several leading laboratories a new method which enables environmental samples to be concentrated to less than 1ml without losing any volatile analytes
Together, SP develops, manufactures and markets a broad line of durable laboratory equipment sold worldwide.
This acquisition will play a critical role in SPs future growth and expansion.
Charles Grant, a Riverlake partner and chief executive officer of SP, will lead Genevac's operations during the consolidation process and beyond.
"As the industry consolidates, we will continue to seek strategic acquisitions that will enable SP to expand its worldwide operating platform, streamline its operations, and more effectively compete in the global marketplace," said Grant.
"By integrating our lines of complementary laboratory equipment products, we can provide our international customer base with a more robust product offering".
Two of Genevac's major product lines include the Genevac EZ2 and HT Series Evaporators and the Mivac concentrators.
The evaporators are designed for drug discovery and research and are typically sold to pharmaceutical and biotechnology companies.
The Mivac concentrator is focused on the life sciences research market, principally for concentrating biologicals.
"Through its SP platform investment, Riverlake has an unparalleled understanding of our industry and its various marketing channels," said Jim Roche, general manager, Genevac.
"Its unique approach to managing portfolio companies makes Riverlake a valued business partner in this transaction, especially as Genevac positions itself for the next stage of growth".
SP's wealth of industry knowledge and management expertise will provide Genevac with strategic, operational and financial support and enable the company to grow and meet the increasing demands of its loyal client base.
In conjunction with the existing management team, Grant will help oversee the development and execution of the company's business strategy and growth plans.
Riverlake has built a solid track record of working with small traditional economy manufacturing and business services companies.
The firm makes controlled investments in companies with proven management teams and high growth potential through a variety of leveraged buyouts, consolidation, recapitalization and growth financing transactions.
Genevac marks Riverlakes eighth leveraged control ownership investment, and the third acquisition in as many weeks.
• Genevac: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
